Neurocrine Biosciences, Inc. (NBIX) Scheduled to Post Quarterly Earnings on Tuesday
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is scheduled to announce its earnings results after the market closes on Tuesday, October 31st. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.01). The business had revenue of $6.34 million during the quarter, compared to analyst estimates of $0.61 million. During the same period in the previous year, the company posted ($0.46) earnings per share. On average, analysts expect Neurocrine Biosciences to post $-2.42 EPS for the current fiscal year and $-1.84 EPS for the next fiscal year.
Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) traded up 0.55% during midday trading on Tuesday, reaching $58.85. The company’s stock had a trading volume of 163,282 shares. Neurocrine Biosciences, Inc. has a 12-month low of $37.35 and a 12-month high of $63.77. The stock’s 50-day moving average price is $59.48 and its 200-day moving average price is $52.12. The company’s market cap is $5.19 billion.
A number of research analysts have recently commented on NBIX shares. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $70.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, September 7th. Jefferies Group LLC reiterated a “buy” rating and issued a $69.00 price objective (up previously from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. ValuEngine upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BMO Capital Markets reiterated an “outperform” rating and issued a $84.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, October 5th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $66.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, September 21st. Two equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Neurocrine Biosciences presently has an average rating of “Buy” and an average target price of $68.81.
In other Neurocrine Biosciences news, insider Christopher Flint Obrien sold 52,817 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $57.50, for a total transaction of $3,036,977.50. Following the completion of the sale, the insider now directly owns 101,790 shares of the company’s stock, valued at approximately $5,852,925. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Dimitri E. Grigoriadis sold 15,354 shares of the stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $55.00, for a total value of $844,470.00. Following the sale, the insider now directly owns 123,045 shares of the company’s stock, valued at $6,767,475. The disclosure for this sale can be found here. Insiders have sold a total of 132,580 shares of company stock valued at $7,440,850 over the last ninety days. 4.80% of the stock is owned by insiders.
A hedge fund recently raised its stake in Neurocrine Biosciences stock. The Manufacturers Life Insurance Company boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,665 shares of the company’s stock after acquiring an additional 193 shares during the quarter. The Manufacturers Life Insurance Company ‘s holdings in Neurocrine Biosciences were worth $123,000 as of its most recent filing with the Securities and Exchange Commission.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.